EIDD-1723, also known as EPRX-01723 or as progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt, is a synthetic, water-soluble analogue of progesterone and a neurosteroid which was developed for the potential treatment of traumatic brain injury.Guthrie, D. B., Lockwood, M. A., Natchus, M. G., Liotta, D. C., Stein, D. G., & Sayeed, I. (2017). U.S. Patent No. 9,802,978. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9802978B2/en It is a rapidly converted prodrug of EIDD-036 (EPRX-036; progesterone 20-oxime), which is considered to be the active form of the agent. Previous C3 and C20 oxime derivatives of progesterone, such as P1-185 (progesterone 3-O-(-valine)-E-oxime), were also developed and studied prior to EIDD-1723.
See also List of neurosteroids § Inhibitory > Synthetic > Pregnanes List of progestogen esters § Oximes of progesterone derivatives
References